InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology
17. September 2018 08:00 ET
|
InspireMD, Inc.
Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA...
InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
04. September 2018 07:30 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
06. August 2018 16:05 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Schedules Second Quarter 2018 Earnings Conference Call
31. Juli 2018 07:00 ET
|
InspireMD, Inc.
Tel Aviv, July 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid...
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
23. Juli 2018 08:41 ET
|
InspireMD, Inc.
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
29. Juni 2018 10:24 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil
20. Juni 2018 07:20 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery
18. Juni 2018 09:42 ET
|
InspireMD, Inc.
Study results presented from 46 patients treated over two years with zero complicationsPresident of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of...
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
11. Juni 2018 09:53 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
30. Mai 2018 07:31 ET
|
InspireMD, Inc.
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...